Cargando…

MicroRNAs in Prion Diseases—From Molecular Mechanisms to Insights in Translational Medicine

MicroRNAs (miRNAs) are small non-coding RNA molecules able to post-transcriptionally regulate gene expression via base-pairing with partially complementary sequences of target transcripts. Prion diseases comprise a singular group of neurodegenerative conditions caused by endogenous, misfolded pathog...

Descripción completa

Detalles Bibliográficos
Autores principales: Contiliani, Danyel Fernandes, Ribeiro, Yasmin de Araújo, de Moraes, Vitor Nolasco, Pereira, Tiago Campos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307047/
https://www.ncbi.nlm.nih.gov/pubmed/34209482
http://dx.doi.org/10.3390/cells10071620
_version_ 1783727957141880832
author Contiliani, Danyel Fernandes
Ribeiro, Yasmin de Araújo
de Moraes, Vitor Nolasco
Pereira, Tiago Campos
author_facet Contiliani, Danyel Fernandes
Ribeiro, Yasmin de Araújo
de Moraes, Vitor Nolasco
Pereira, Tiago Campos
author_sort Contiliani, Danyel Fernandes
collection PubMed
description MicroRNAs (miRNAs) are small non-coding RNA molecules able to post-transcriptionally regulate gene expression via base-pairing with partially complementary sequences of target transcripts. Prion diseases comprise a singular group of neurodegenerative conditions caused by endogenous, misfolded pathogenic (prion) proteins, associated with molecular aggregates. In humans, classical prion diseases include Creutzfeldt–Jakob disease, fatal familial insomnia, Gerstmann–Sträussler–Scheinker syndrome, and kuru. The aim of this review is to present the connections between miRNAs and prions, exploring how the interaction of both molecular actors may help understand the susceptibility, onset, progression, and pathological findings typical of such disorders, as well as the interface with some prion-like disorders, such as Alzheimer’s. Additionally, due to the inter-regulation of prions and miRNAs in health and disease, potential biomarkers for non-invasive miRNA-based diagnostics, as well as possible miRNA-based therapies to restore the levels of deregulated miRNAs on prion diseases, are also discussed. Since a cure or effective treatment for prion disorders still pose challenges, miRNA-based therapies emerge as an interesting alternative strategy to tackle such defying medical conditions.
format Online
Article
Text
id pubmed-8307047
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83070472021-07-25 MicroRNAs in Prion Diseases—From Molecular Mechanisms to Insights in Translational Medicine Contiliani, Danyel Fernandes Ribeiro, Yasmin de Araújo de Moraes, Vitor Nolasco Pereira, Tiago Campos Cells Review MicroRNAs (miRNAs) are small non-coding RNA molecules able to post-transcriptionally regulate gene expression via base-pairing with partially complementary sequences of target transcripts. Prion diseases comprise a singular group of neurodegenerative conditions caused by endogenous, misfolded pathogenic (prion) proteins, associated with molecular aggregates. In humans, classical prion diseases include Creutzfeldt–Jakob disease, fatal familial insomnia, Gerstmann–Sträussler–Scheinker syndrome, and kuru. The aim of this review is to present the connections between miRNAs and prions, exploring how the interaction of both molecular actors may help understand the susceptibility, onset, progression, and pathological findings typical of such disorders, as well as the interface with some prion-like disorders, such as Alzheimer’s. Additionally, due to the inter-regulation of prions and miRNAs in health and disease, potential biomarkers for non-invasive miRNA-based diagnostics, as well as possible miRNA-based therapies to restore the levels of deregulated miRNAs on prion diseases, are also discussed. Since a cure or effective treatment for prion disorders still pose challenges, miRNA-based therapies emerge as an interesting alternative strategy to tackle such defying medical conditions. MDPI 2021-06-29 /pmc/articles/PMC8307047/ /pubmed/34209482 http://dx.doi.org/10.3390/cells10071620 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Contiliani, Danyel Fernandes
Ribeiro, Yasmin de Araújo
de Moraes, Vitor Nolasco
Pereira, Tiago Campos
MicroRNAs in Prion Diseases—From Molecular Mechanisms to Insights in Translational Medicine
title MicroRNAs in Prion Diseases—From Molecular Mechanisms to Insights in Translational Medicine
title_full MicroRNAs in Prion Diseases—From Molecular Mechanisms to Insights in Translational Medicine
title_fullStr MicroRNAs in Prion Diseases—From Molecular Mechanisms to Insights in Translational Medicine
title_full_unstemmed MicroRNAs in Prion Diseases—From Molecular Mechanisms to Insights in Translational Medicine
title_short MicroRNAs in Prion Diseases—From Molecular Mechanisms to Insights in Translational Medicine
title_sort micrornas in prion diseases—from molecular mechanisms to insights in translational medicine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307047/
https://www.ncbi.nlm.nih.gov/pubmed/34209482
http://dx.doi.org/10.3390/cells10071620
work_keys_str_mv AT contilianidanyelfernandes micrornasinpriondiseasesfrommolecularmechanismstoinsightsintranslationalmedicine
AT ribeiroyasmindearaujo micrornasinpriondiseasesfrommolecularmechanismstoinsightsintranslationalmedicine
AT demoraesvitornolasco micrornasinpriondiseasesfrommolecularmechanismstoinsightsintranslationalmedicine
AT pereiratiagocampos micrornasinpriondiseasesfrommolecularmechanismstoinsightsintranslationalmedicine